The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of ...

Initial study results for ISB 2001, which treats relapsed or refractory multiple myeloma, demonstrated a high overall ...

IGI, Inc., a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, ...

The Fast Track status is intended to accelerate the development and review process for drugs addressing serious conditions ...

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term ...

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in transplant-ineligible, newly diagnosed multiple myeloma.

"A drug receiving fast track tag also may be eligible for priority review if relevant criteria are met. ISB 2001 was ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for ...